AR034159A1 - Derivados de 5-amino-1-penten-3-ol sustituidos, procedimiento para su preparacion, medicamentos que contienen estos derivados y su uso para la preparacion de medicamentos - Google Patents

Derivados de 5-amino-1-penten-3-ol sustituidos, procedimiento para su preparacion, medicamentos que contienen estos derivados y su uso para la preparacion de medicamentos

Info

Publication number
AR034159A1
AR034159A1 ARP010104584A ARP010104584A AR034159A1 AR 034159 A1 AR034159 A1 AR 034159A1 AR P010104584 A ARP010104584 A AR P010104584A AR P010104584 A ARP010104584 A AR P010104584A AR 034159 A1 AR034159 A1 AR 034159A1
Authority
AR
Argentina
Prior art keywords
unsubstituted
mono
polysubstituted
unsaturated
saturated
Prior art date
Application number
ARP010104584A
Other languages
English (en)
Inventor
Helmut Heinrich Buschmann
Maul Corinna Dr
Bernd Sundermann
Haurand Michael Dr
Chizh Boris Dr
Utz-Peter Jagusch
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of AR034159A1 publication Critical patent/AR034159A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Abstract

Derivados de 5-amino-1-penten-3-ol sustituidos, de la fórmula general (1), en la cual: R1 y R2 representan independientemente entre sí alquilo C1-6 de cadena recta o ramificada, saturado o insaturado, no sustituido o mono o polisustituido, o R1 y R2 representan conjuntamente un ciclo (CH2)2-9, eventualmente sustituido con alquilo C1-8, de cadena recta o ramificada, saturado o insaturado, no sustituido o mono o polisustituido, o arilo no sustituido o mono o polisustituido; R3 y R4 representan independientemente entre sí alquilo C1-6, saturado o no saturado, ramificado o no ramificado, no sustituido o mono o polisustituido, cicloalquilo C3-6 saturado o no saturado, no sustituido o mono o polisustituido, fenilo, bencilo o fenetilo, no sustituidos o mono o polisustituidos, o R3 y R4 en conjunto forman un ciclo y representan (CH2)3-6 ó CH2CH2OCH2CH2; R5 representa alquilo C1-10 saturado o insaturado, ramificado o no ramificado, no sustituido o mono o polisustituido, cicloalquilo C3-9 saturado o insaturado, arilo o heteroarilo, arilo ligado a través de alquilo C1-3 saturado o no saturado, cicloalquilo C3-10 ligado a través de alquilo C1-3 saturado o no saturado, o heteroarilo ligado a través de alquilo C1-3 saturado o no saturado, en donde todos los radicales arilo, heteroarilo y cicloalquilo pueden ser no sustituido o mono o polisustituidos con sustituyentes elegidos independientemente entre sí entre F, Cl, Br, I, OR18, SR18, SO2R18, SO2OR18, CN, COOR18, NR19R20, alquilo C1-10 saturado o insaturado, ramificado o no ramificado, no sustituido o mono o polisustituido, cicloalquilo C3-9 saturado o insaturado, no sustituido o mono o polisustituido, arilo o heteroarilo, no sustituido o mono o polisustituido, arilo, cicloalquilo C3-9 o heteroarilo ligados a través de alquilo C1-3 saturado o no saturado, no sustituido o mono o polisustituidos; R18 representa H, alquilo C1-10 saturado o insaturado, ramificado o no ramificado, no sustituido o mono o polisustituido, cicloalquilo C3-9 saturado o insaturado, no sustituido o mono o polisustituido, arilo o heteroarilo, no sustituido o mono o polisustituido, arilo, cicloalquilo C3-9 o heteroarilo, no sustituido o mono o polisustituidos ligados a través de alquilo C1-3 saturado o insaturado; R19 y R20 representan independientemente entre sí H, alquilo C1-10 saturado o insaturado, ramificado o no ramificado, no sustituido o mono o polisustituido, cicloalquilo C3-9 saturado o insaturado, no sustituido o mono o polisustituido, arilo o heteroarilo, no sustituido o mono o polisustituido, arilo, cicloalquilo C3-9 o heteroarilo, no sustituido o mono o polisustituidos ligados a través de alquilo C1-3 saturado o insaturado, o R19 y R20 en conjunto representan CH2CH2OCH2CH2, CH2CH2NR21CH2CH2 ó (CH2)3-6; R21 representa H o alquilo C1-10 saturado o insaturado, ramificado o no ramificado, no sustituido o mono o polisustituido; R6 representa alquilo C1-10 saturado o insaturado, ramificado o no ramificado, no sustituido o mono o polisustituido, cicloalquilo C5-7, arilo o heteroarilo, no sustituidos o mono o polisustituidos; R7 representa H, arilo o heteroarilo no sustituidos o mono o polisustituidos; en forma de sus racematos, enantiómeros, diastereómeros, particularmente mezclas de sus enantiómeros o diastereómeros o un enantiómero o diastereómero o enantiómero individual; en forma de sus sales ácidas o básicas o sales con cationes o bases o con aniones o ácidos fisiológicamente tolerables, o en forma de sus ácidos o bases libres, procedimiento para su preparación, medicamentos que contienen estos derivados y su uso para la preparación de medicamentos, para el tratamiento de dolores, particularmente dolores neuropáticos, crónicos o agudos, migranas, hiperalgesia y alodinia, particularmente hiperalgesia térmica, hiperlagesia mecánica, alodinia y crioalodinia o de dolores inflamatorios o postoperatorios, epilepsia, calores y otros desórdenes postmenopáusicos, esclerosis lateral amiotrofica (ALS), distrofia simpática refleja (RSD), parálisis espastica, síndrome de las piernas inquietas, nistagmo adquirido, afecciones psiquiatricas o neuropatológicas, tales como perturbaciones bipolares, ansiedad, ataques de pánico, modificaciones de carácter, comportamiento maníaco, depresiones, comportamiento maniaco-depresivo, neuropatía diabética dolorosa, síntomas y dolores resultantes de esclerosis múltiple o enfermedad de Parkinson, enfermedades neurodegenerativas tales como enfermedad de Alzheimer, enfermedad de Huntington, enfermedad de Parkinson y epilepsia, lesiones gastrointestinales; dolores eritromelalgicos o postpoliomielíticos, neuralgia del trigemino o postherpetica, o como anticonvulsivo, analgésico o ansiolitico.
ARP010104584A 2000-09-30 2001-09-28 Derivados de 5-amino-1-penten-3-ol sustituidos, procedimiento para su preparacion, medicamentos que contienen estos derivados y su uso para la preparacion de medicamentos AR034159A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10048714A DE10048714A1 (de) 2000-09-30 2000-09-30 5-Amino-1-penlen-3-ol-Derivate

Publications (1)

Publication Number Publication Date
AR034159A1 true AR034159A1 (es) 2004-02-04

Family

ID=7658375

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104584A AR034159A1 (es) 2000-09-30 2001-09-28 Derivados de 5-amino-1-penten-3-ol sustituidos, procedimiento para su preparacion, medicamentos que contienen estos derivados y su uso para la preparacion de medicamentos

Country Status (29)

Country Link
US (1) US6815443B2 (es)
EP (1) EP1322590B1 (es)
JP (1) JP2004511458A (es)
KR (1) KR20030059161A (es)
CN (1) CN1649826A (es)
AR (1) AR034159A1 (es)
AT (1) ATE361274T1 (es)
AU (3) AU2002212263A1 (es)
BR (1) BR0114459A (es)
CA (1) CA2424103A1 (es)
CY (1) CY1106712T1 (es)
DE (2) DE10048714A1 (es)
DK (1) DK1322590T3 (es)
EC (1) ECSP034533A (es)
ES (1) ES2286154T3 (es)
HK (1) HK1053103A1 (es)
HU (1) HUP0303110A3 (es)
IL (1) IL155104A0 (es)
MX (1) MXPA03002734A (es)
MY (1) MY127328A (es)
NO (1) NO20031388L (es)
NZ (1) NZ525250A (es)
PE (1) PE20020446A1 (es)
PL (1) PL362398A1 (es)
PT (1) PT1322590E (es)
RU (1) RU2289571C2 (es)
SK (1) SK286785B6 (es)
WO (2) WO2002028816A1 (es)
ZA (1) ZA200303301B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10049483A1 (de) * 2000-09-29 2002-05-02 Gruenenthal Gmbh Substituierte 1-Aminobutan-3-ol-Derivate
BR0306811A (pt) * 2002-01-11 2004-10-26 Sankyo Co Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
KR20110136901A (ko) 2004-02-24 2011-12-21 상꾜 가부시키가이샤 아미노 알코올 화합물
CN104521963A (zh) * 2014-12-31 2015-04-22 江阴苏利化学股份有限公司 一种含有环己酮的防治水稻二化螟的农药组合物
CN115745922B (zh) * 2022-11-22 2024-02-20 沈阳药科大学 藏东瑞香中的二芳基戊烷类化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE239403C (es)
NL6407943A (es) * 1964-07-11 1966-01-12
CH500162A (de) * 1968-05-20 1970-12-15 Ankermann & Co Vitaminchemie F Verfahren zur Herstellung von D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol aus L-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol
US3974157A (en) * 1974-03-04 1976-08-10 Pennwalt Corporation 1-(Amino-alkyl)-2-aryl-cyclohexane alcohols and esters
FR2559765B1 (fr) * 1984-02-16 1986-06-13 Rhone Poulenc Sante Nouveaux derives de la phenyl-3 propene-2 amine, leur preparation et les medicaments qui les contiennent
GB2323594A (en) * 1997-03-25 1998-09-30 Victor Martin 2-amino-alkanoic acid derivatives, 2-amino alcohols and diamines
WO1999037296A1 (en) * 1998-01-23 1999-07-29 Warner-Lambert Company Gabapentin and its derivatives for the treatment of muscular and skeletal pain
AU758103B2 (en) * 1998-07-09 2003-03-13 Warner-Lambert Company Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain
AU5478799A (en) * 1998-09-14 2000-04-03 Warner-Lambert Company Branched alkyl pyrrolidine-3-carboxylic acids

Also Published As

Publication number Publication date
NO20031388D0 (no) 2003-03-26
SK286785B6 (sk) 2009-05-07
HUP0303110A2 (hu) 2004-03-01
AU2002221632B8 (en) 2006-05-18
ZA200303301B (en) 2004-08-12
CN1649826A (zh) 2005-08-03
US20030220390A1 (en) 2003-11-27
HUP0303110A3 (en) 2006-02-28
ATE361274T1 (de) 2007-05-15
PE20020446A1 (es) 2002-05-18
NO20031388L (no) 2003-05-22
US6815443B2 (en) 2004-11-09
DE50112454D1 (de) 2007-06-14
SK3392003A3 (en) 2003-09-11
IL155104A0 (en) 2003-10-31
AU2002221632B2 (en) 2006-04-27
WO2002030869A1 (de) 2002-04-18
PT1322590E (pt) 2007-05-31
CA2424103A1 (en) 2003-03-28
HK1053103A1 (zh) 2003-10-10
BR0114459A (pt) 2003-09-23
EP1322590A1 (de) 2003-07-02
DK1322590T3 (da) 2007-09-03
ES2286154T3 (es) 2007-12-01
PL362398A1 (en) 2004-11-02
RU2289571C2 (ru) 2006-12-20
WO2002028816A1 (en) 2002-04-11
AU2163202A (en) 2002-04-22
EP1322590B1 (de) 2007-05-02
ECSP034533A (es) 2003-05-26
NZ525250A (en) 2005-11-25
MXPA03002734A (es) 2003-07-28
AU2002212263A1 (en) 2002-04-15
DE10048714A1 (de) 2002-04-11
CY1106712T1 (el) 2012-05-23
KR20030059161A (ko) 2003-07-07
JP2004511458A (ja) 2004-04-15
MY127328A (en) 2006-11-30

Similar Documents

Publication Publication Date Title
AR034158A1 (es) Derivados de 1-aminobutano-3-ol sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y el uso de derivados de 1-aminobutano-3-ol sustituidos para la preparacion de medicamentos
AR034160A1 (es) Sulfonilguanidinas, medicamentos que contienen estos compuestos y el uso de sulfonilguanidinas
AR040773A1 (es) Pirazoles utiles como inhibidores de gsk-3
AR070398A1 (es) Derivados sustituidos de indol
JP2005527593A5 (es)
AR054557A1 (es) Tienopirimidinonas, tienopiridazinonas y tienotriazinonas para el tratamiento de obesidad
CO5580820A2 (es) Derivados novedosos de acido (2s)-3-(4-{2-[amino]-2-oxoetoxi} fenil)-2-etoxipropanoico procesos para su preparacion y composiciones farmaceuticas que los contienen
AR050297A1 (es) Hidantoinas sustituidas
AR056004A1 (es) Derivados de pirrolo[2, 3 -d]pirimidina, metodos de sintesis de los mismos y sus intermediarios de preparacion
AR050261A2 (es) Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento
AR034159A1 (es) Derivados de 5-amino-1-penten-3-ol sustituidos, procedimiento para su preparacion, medicamentos que contienen estos derivados y su uso para la preparacion de medicamentos
MA38272A1 (fr) Peptides en tant qu'agonistes de l'oxytocine
HRP20110196T1 (hr) 3,5-disupstituirani fenil-piperidini kao modulatori dopamina neurotransmisije
AR070885A1 (es) Compuestos de azaindol para el tratamiento de trastornos del sistema nervioso central
HRP20201473T1 (hr) Inhibitori lizin gingipaina
ES2517602T3 (es) Derivados arilamida sustituidos con tetrazol y su utilización como antagonistas de receptores purinérgicos P2X3 y/o P2X2/3
AR035062A1 (es) Derivados de c-ciclohexilmetilamina sustituidos, medicamentos que contienen estos compuestos y el uso de derivados de c-ciclohexilmetilamina sustituidos para la preparacion de medicamentos
US11618751B1 (en) Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
AR034265A1 (es) Aminoacidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y el uso de aminoacidos para la preparacion de medicamentos para el tratamiento de dolores
AR041931A1 (es) Derivados de la ciclohexilurea, metodos de preparacion y su empleo en la elaboracion de medicamentos
AR068467A1 (es) Compuestos de nicotinamida sustituida y sus usos en medicamentos
ES2343624T3 (es) Derivados de prolina que tienen afinidad por la subunidad alfa-2-delta del canal de calcio.
ES2650139T3 (es) Compuestos 3-fenilsulfanilmetil-biciclo[3.1.0]hexano 4-sustituidos como antagonistas de mGluR 2/3
AR048326A1 (es) Derivados de prolinilo
JP2012501336A (ja) シンナミド化合物の製造法

Legal Events

Date Code Title Description
FA Abandonment or withdrawal